Detalles de la búsqueda
1.
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
N Engl J Med
; 381(16): 1535-1546, 2019 10 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-31562797
2.
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Lancet Oncol
; 19(11): 1480-1492, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30361170
3.
TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma.
Cancer Immunol Res
; 9(10): 1202-1213, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34389558
4.
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204).
Neuro Oncol
; 23(11): 1961-1973, 2021 11 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33880555
5.
A Machine-Learning Approach to Identify a Prognostic Cytokine Signature That Is Associated With Nivolumab Clearance in Patients With Advanced Melanoma.
Clin Pharmacol Ther
; 107(4): 978-987, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31721173
6.
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.
JAMA Oncol
; 5(2): 187-194, 2019 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30422243
Resultados
1 -
6
de 6
1
Próxima >
>>